DermTech's low P/S ratio is likely due to limited future growth expectations. Poor revenue performance and a lower-than-industry growth forecast have reduced investor willingness to pay more for the stock. A significant change in fortune is needed for a higher P/S ratio.
$DermTech(DMTK.US)$DermTech Announces Restructuring Actions And Emphasis On Growing Revenue For DermTech Melanoma Test ; Co. To Reduce 15% Of Workforce, Expects ~$40M In Total Operating Expense Reductions
$DermTech(DMTK.US)$DermTech Announces Topline Results From Study Evaluating DermTech Melanoma Test Across All Skin Types; Negative Predictive Value Higher Than 99% Regardless Of Skin Type
QUICK SCALP 5 $DMTK — STOCK & OPTION PLAY ALERT ON: $5.08 ON THE WATCH: $5.15 🥇 SIGNED OF MORE UPTREND: $5.23 NEED IT TO BREAK OVER: $5.37 key indicator for MORE uptrend $5.52 confirmation uptrend - $5.73 mini breakout - $5.95.$DermTech(DMTK.US)$
Gainers: •$Rocket Pharmaceuticals(RCKT.US)$+10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy) •$加拿大鵝(GOOS.US)$+9.4% (the company reported an unexpected profit as well as better-than-expected revenue) •$SIGA Technologies(SIGA.US)$+6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
DermTech股票討論區
Update
Update
ok 👀 👀
ALERT ON: $5.08
ON THE WATCH: $5.15
🥇 SIGNED OF MORE UPTREND: $5.23
NEED IT TO BREAK OVER: $5.37
key indicator for MORE uptrend $5.52
confirmation uptrend - $5.73
mini breakout - $5.95. $DermTech(DMTK.US)$
AH+1/11 Watchlist
$艾伯維公司(ABBV.US)$$博通(AVGO.US)$$BioAtla(BCAB.US)$$Biora Therapeutics(BIOR.US)$$DermTech(DMTK.US)$ $Broadwind(BWEN.US)$$CureVac(CVAC.US)$$EVgo Inc(EVGO.US)$$Hepion Pharmaceuticals(HEPA.US)$$尚乘數科(HKD.US)$$Ichor Holdings(ICHR.US)$$萬事達(MA.US)$$NextPlay Technologies(NXTP.US)$$Party City Holdco(PRTY.US)$$星巴克(SBUX.US)$
專欄Today's pre-market stock movers: GOOS, TSLA, KSS, UAA and more
• $Rocket Pharmaceuticals(RCKT.US)$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $加拿大鵝(GOOS.US)$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US)$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
i closed my positions in these growth stocks post market today. sick.
暫無評論